AI channel feed

Bet­ting ear­ly on an AI niche, RA Cap­i­tal seeds a young founder's quest to un­lock 'Holy Grail' tar­gets

5 years ago
Financing
Startups

Ex­clu­sive: Mi­crosoft, Sam Alt­man back a new AI biotech up­start

5 years ago
Startups

Daphne Koller lines up $400M for a glob­al shop­ping spree to vault for­ward on AI drug dis­cov­ery

5 years ago
Financing

Black­Rock push­es Ex­sci­en­tia Se­ries C to $100M as AI biotech boom con­tin­ues

5 years ago
Financing

In­sil­i­co preps first can­di­date for IND stud­ies, hop­ing to launch tri­al in IPF by end of 2021

5 years ago

Wad­ing deep­er in­to tar­get dis­cov­ery and val­i­da­tion, Im­mu­nai bags $60M to beef up both AI al­go­rithms and lab bench­es

5 years ago
Financing

Dyno sketch­es tens of thou­sands of vi­able next-gen AAV cap­sids with the help of ma­chine learn­ing — pa­per

5 years ago
Cell/Gene Tx

On the hunt for a bet­ter an­ti­body, BigHat Bio­sciences de­buts with $19M Se­ries A to scale its 'wet lab' AI plat­form

5 years ago
Financing

Roche and Genen­tech's lat­est AI col­lab­o­ra­tor rais­es $25M Se­ries A to rein­vent one of the old­est can­cer tar­gets

5 years ago
Financing

As­traZeneca scores new goal on the pipeline front, adding its first AI-gen­er­at­ed tar­get to the port­fo­lio

5 years ago
R&D

On a mis­sion to 'u­ni­fy' drug dis­cov­ery and cell-line de­vel­op­ment, Ab­Sci ac­quires AI out­fit De­n­ovi­um

5 years ago
Deals

Look­ing to solve pub­lic health crises through dis­cov­ery, Gates Foun­da­tion taps AI firm Ex­sci­en­tia to look for an­swers

5 years ago
Discovery

Pear Ther­a­peu­tics nabs $80M Se­ries D to com­mer­cial­ize three dig­i­tal ther­a­peu­tics

5 years ago
Financing

A Genen­tech-part­nered Vi­jay Pande fa­vorite nabs $52M to ad­vance an AI pipeline

5 years ago
Financing

Bris­tol My­er­s' Richard Har­g­reaves pays $70M to launch a neu­rode­gen­er­a­tion al­liance with a star play­er in the ma­chine learn­ing world

5 years ago
Deals

Roche's James Sabry inks his sec­ond AI deal in back-to-back pacts — this time part­ner­ing Genen­tech with Stan­ford spin­out Gen­e­sis Ther­a­peu­tics

5 years ago
Deals

Jim Al­li­son and Pam Shar­ma back a Cana­di­an AI up­start seek­ing to solve the tu­mor stro­ma puz­zle

5 years ago
R&D

GSK, As­traZeneca plan to har­ness AI pow­er for drug de­vel­op­ment from Nvidi­a's new, $50M-plus su­per­com­put­er now un­der con­struc­tion

5 years ago
R&D

Bid­ding to be the go-to ge­nomics and da­ta part­ner for drug de­vel­op­ment, Sophia Ge­net­ics rais­es $100M

5 years ago
Financing

Mer­ck­'s Roger Perl­mut­ter makes a rare move, join­ing the board of a ma­chine learn­ing start­up out to change the R&D world. And he has some thoughts on that

5 years ago
People

Soft­Bank, Morn­ing­side help put US-Chi­na AI play­er on the map with $318M bet

5 years ago
Financing
China

Us­ing AI to se­quence fun­gi genomes for can­cer treat­ments, Hexa­gon Bio nets $47M in Se­ries A

5 years ago
Financing
R&D

As Chi­na's tech gi­ants catch on­to biotech, Baidu plots $2B start­up fo­cused on di­ag­no­sis, AI drug dis­cov­ery

5 years ago
Financing
China

FL56+FL57= in­fi­nite pos­si­bil­i­ties? Flag­ship's hy­brid start­up takes ma­chine learn­ing in drug dis­cov­ery to the next lev­el — and Covid-19 of­fers a quick test

5 years ago
Startups
First page Previous page 9101112131415 Next page Last page
A service from the Financial Times